Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
14 CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Hamborsky J, McIntyre L, Wolfe S., eds. 9th ed. Washington, DC: Public Health Foundation;, 2006:24–-25, 143. 15 CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Hamborsky J, McIntyre L, Wolfe S., eds. 9th ed. Washington DC: Public Health Foundation;, 2006:24–-25, 143. 16 CDC National Center for Health Statistics. Skin test preparation steps: filling syringes. In: Skin Test Preparation Steps: Filling Syringes. National Health and Nutrition Examination Survey (NHANES) Manual. Hyattsville, MD: National Center for Health Statistics. 17 CDC. Part two: reading the Mantoux tuberculin skin test. Mantoux Tuberculin Skin Test Facilitator Guide [Division Tuberculosis Elimination Web site]. Available online at: http://www.cdc.gov/tb/pubs/Mantoux/guide.htm . Accessed November 30, 2010. 18 CDC. Tuberculin skin testing. In: Chapter 3: testing for TB disease and infection. Core Curriculum on Tuberculosis (2011). Updated 2011. ) [Division of Tuberculosis Elimination Web site]. Available at: . http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm Accessed December 2, 2010: http://www.cdc.gov/tb/pubs/corecurr/default.htm . Accessed February 6, 2007. 19 CDC. Tuberculin skin testing. In: Chapter 3: testing for TB disease and infection. Core Curriculum on Tuberculosis (2011). Updated 2011. ) [Division of Tuberculosis Elimination Web site]. Available at: . http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm Accessed December 2, 2010. 20 CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55(No. RR-14):1–17. 21 ® CDC. Guidelines for using the QuantiFERON -TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):52. 22 CDC.Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection, United States, 2010 (MMWR 2010; 59 [No. RR-5];1-25) at http://www.cdc.gov/mmwr/PDF/rr/rr5905.pdf 23 CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(No. RR-17):4. 24 Curry International Tuberculosis Center. Diagnosis and Treatment [Web page]. Available online at http://currytbcenter.ucsf.edu/abouttb/diagnosis_and_treatment.cfm Accessed October28, 2011. 25 Curry International Tuberculosis Center. Diagnosis and Treatment [Web page]. Available online at http://currytbcenter.ucsf.edu/abouttb/diagnosis_and_treatment.cfm Accessed October28, 2011. 26 CDC, Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No RR-15):52. 27 ® CDC. Guidelines for using the QuantiFERON -TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR. 2005;54(No. RR-15):52 28 ® CDC. Guidelines for using the QuantiFERON -TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR. 2005;54(No. RR-15):52. 29 CDC, Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR. 2005;54(No. RR-15):52. 30 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):25. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Diagnosis of Latent Tuber culosis Infection 7 . 22 R e v i s e d N o v e m b e r 2 0 1 2
Treatment of Latent Tuberculosis Infection CONTENTS Introduction ............................................. 8.2 Purpose................................................................ 8.2 Policy ................................................................... 8.3 Forms ................................................................... 8.3 Whom to Treat ......................................... 8.4 Window period prophylaxis for susceptible and vulnerable contacts .............................................. 8.4 Tuberculin skin test results of 5 mm or more ....... 8.5 Tuberculin skin test results of 10 mm or more ..... 8.5 Treatment Regimens and Dosages....... 8.6 Regimens ............................................................. 8.7 New 12-week Isoniazid-Rifapentine regimen ....... 8.8 Dosages ............................................................... 8.9 Pyridoxine (Vitamin B6) ..................................... 8.10 Side Effects and Adverse Reactions .. 8.11 Basic monitoring steps ....................................... 8.11 Reporting reactions ............................................ 8.12 Monitoring for side effects and adverse reactions by antituberculosis drug ..................... 8.13 Adherence ............................................. 8.16 Monthly assessment of adherence .................... 8.16 Directly observed therapy .................................. 8.16 Completion of Therapy ........................ 8.18 Treatment in Special Situations .......... 8.20 Human immunodeficiency virus and latent tuberculosis infection ......................................... 8.20 Alcoholism .......................................................... 8.21 Pregnancy and breastfeeding ............................ 8.23 Resources and References ................. 8.24 A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Tr eatment of Latent Tuberculosis Infection Revised November 2012 8.1
- Page 103 and 104: Figure 1:TREATMENT ALGORITHM FOR DR
- Page 105 and 106: a. In remote locations in Alaska, m
- Page 107 and 108: Antituberculosis Drug Rifampin (RIF
- Page 109 and 110: Antituberculosis Drug Rifapentine (
- Page 111 and 112: Reporting Reactions The table below
- Page 113 and 114: Response to Treatment For consultat
- Page 115 and 116: Figure 2: MANAGEMENT OF TREATMENT I
- Page 117 and 118: Post-Treatment Evaluation Routine f
- Page 119 and 120: Treatment in Special Situations Tre
- Page 121 and 122: Resources For consultation regardin
- Page 123 and 124: with an increase in overall complet
- Page 125 and 126: Liver Disease Management of TB in p
- Page 127 and 128: After the initial phase (first two
- Page 129 and 130: Extrapulmonary Tuberculosis The bas
- Page 131 and 132: Resources and References Resources
- Page 133 and 134: Diagnosis of Latent Tuberculosis In
- Page 135 and 136: Forms All required and recommended
- Page 137 and 138: High-Risk Groups Certain factors id
- Page 139 and 140: Diagnosis of Latent Tuberculosis In
- Page 141 and 142: continually exposed to populations
- Page 143 and 144: Administration of the Tuberculin Sk
- Page 145 and 146: See “Two-Step Tuberculin Skin Tes
- Page 147 and 148: See “Live-Virus Vaccines” under
- Page 149 and 150: For more information on IGRAs and t
- Page 151 and 152: Table 5: TARGETED TESTING FOR LATEN
- Page 153: Resources and References Resources
- Page 157 and 158: Policy Detailed information on the
- Page 159 and 160: Window period prophylaxis is treatm
- Page 161 and 162: Regimens Identify an appropriate re
- Page 163 and 164: Dosages Once the appropriate regime
- Page 165 and 166: Side Effects and Adverse Reactions
- Page 167 and 168: If a patient reports to a healthcar
- Page 169 and 170: Antituberculosis Drug Rifampin (RIF
- Page 171 and 172: DOT is strongly encouraged for thos
- Page 173 and 174: Table 7 describes the duration of t
- Page 175 and 176: Alcoholism Alcohol-Related Treatmen
- Page 177 and 178: Medication Administration and Pharm
- Page 179 and 180: National Tuberculosis Controllers A
- Page 181 and 182: 24 CDC . “Recommendations for Use
- Page 183 and 184: Diagnosis and Treatment of Latent T
- Page 185 and 186: All children suspected or diagnosed
- Page 187 and 188: Latent Tuberculosis Infection (LTBI
- Page 189 and 190: History of BCG vaccination is not a
- Page 191 and 192: Because of their higher specificity
- Page 193 and 194: Table 3: COUNTRIES AND AREAS WITH A
- Page 195 and 196: Treatment of Latent TB Infection (L
- Page 197 and 198: For consultation regarding the trea
- Page 199 and 200: Monitoring DOT is mandatory for INH
- Page 201 and 202: For young infants, some experts rec
- Page 203 and 204: TABLE 8: SIGNS AND SYMPTOMS OF PULM
14<br />
CDC. <strong>Epidemiology</strong> and Prevention <strong>of</strong> Vaccine-Preventable Diseases. Atkinson W, Hamborsky J, McIntyre L, Wolfe S.,<br />
eds. 9th ed. Washington, DC: Public Health Foundation;, 2006:24–-25, 143.<br />
15<br />
CDC. <strong>Epidemiology</strong> and Prevention <strong>of</strong> Vaccine-Preventable Diseases. Atkinson W, Hamborsky J, McIntyre L, Wolfe S.,<br />
eds. 9th ed. Washington DC: Public Health Foundation;, 2006:24–-25, 143.<br />
16<br />
CDC National Center for Health Statistics. Skin test preparation steps: filling syringes. In: Skin Test Preparation Steps:<br />
Filling Syringes. National Health and Nutrition Examination Survey (NHANES) <strong>Manual</strong>. Hyattsville, MD: National Center<br />
for Health Statistics.<br />
17<br />
CDC. Part two: reading the Mantoux tuberculin skin test. Mantoux Tuberculin Skin Test Facilitator Guide [Division<br />
<strong>Tuberculosis</strong> Elimination Web site]. Available online at: http://www.cdc.gov/tb/pubs/Mantoux/guide.htm . Accessed<br />
November 30, 2010.<br />
18<br />
CDC. Tuberculin skin testing. In: Chapter 3: testing for TB disease and infection. Core Curriculum on <strong>Tuberculosis</strong><br />
(2011). Updated 2011. ) [Division <strong>of</strong> <strong>Tuberculosis</strong> Elimination Web site]. Available at: .<br />
http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm Accessed December 2, 2010:<br />
http://www.cdc.gov/tb/pubs/corecurr/default.htm . Accessed February 6, 2007.<br />
19<br />
CDC. Tuberculin skin testing. In: Chapter 3: testing for TB disease and infection. Core Curriculum on <strong>Tuberculosis</strong><br />
(2011). Updated 2011. ) [Division <strong>of</strong> <strong>Tuberculosis</strong> Elimination Web site]. Available at: .<br />
http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm Accessed December 2, 2010.<br />
20<br />
CDC. Revised recommendations for HIV testing <strong>of</strong> adults, adolescents, and pregnant women in health-care settings.<br />
MMWR 2006;55(No. RR-14):1–17.<br />
21 ®<br />
CDC. Guidelines for using the QuantiFERON -TB Gold test for detecting Mycobacterium tuberculosis infection, United<br />
<strong>State</strong>s. MMWR 2005;54(No. RR-15):52.<br />
22<br />
CDC.Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis<br />
Infection, United <strong>State</strong>s, 2010 (MMWR 2010; 59 [No. RR-5];1-25) at http://www.cdc.gov/mmwr/PDF/rr/rr5905.pdf<br />
23<br />
CDC. Guidelines for preventing the transmission <strong>of</strong> Mycobacterium tuberculosis in health-care settings, 2005. MMWR<br />
2005;54(No. RR-17):4.<br />
24<br />
Curry International <strong>Tuberculosis</strong> Center. Diagnosis and Treatment [Web page]. Available online at<br />
http://currytbcenter.ucsf.edu/abouttb/diagnosis_and_treatment.cfm Accessed October28, 2011.<br />
25<br />
Curry International <strong>Tuberculosis</strong> Center. Diagnosis and Treatment [Web page]. Available online at<br />
http://currytbcenter.ucsf.edu/abouttb/diagnosis_and_treatment.cfm Accessed October28, 2011.<br />
26<br />
CDC, Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United<br />
<strong>State</strong>s. MMWR 2005;54(No RR-15):52.<br />
27 ®<br />
CDC. Guidelines for using the QuantiFERON -TB Gold test for detecting Mycobacterium tuberculosis infection, United<br />
<strong>State</strong>s. MMWR. 2005;54(No. RR-15):52<br />
28 ®<br />
CDC. Guidelines for using the QuantiFERON -TB Gold test for detecting Mycobacterium tuberculosis infection, United<br />
<strong>State</strong>s. MMWR. 2005;54(No. RR-15):52.<br />
29<br />
CDC, Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United<br />
<strong>State</strong>s. MMWR. 2005;54(No. RR-15):52.<br />
30<br />
CDC. Targeted tuberculin testing and treatment <strong>of</strong> latent tuberculosis infection. MMWR 2000;49(No. RR-6):25.<br />
A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Diagnosis <strong>of</strong> Latent Tuber culosis Infection 7 . 22<br />
R e v i s e d N o v e m b e r 2 0 1 2
Change language